At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 10 enrolled
Drug / intervention
Ranibizumab injection and TTT - ICG baseddrug
Likely dose
Ranibizumab injection and TTT - ICG based 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma
In Brief
A Phase 3 clinical trial evaluating Ranibizumab injection and TTT - ICG based for Choroidal Melanoma. Completed, enrolled 10 participants across 1 site.
Detailed Summary
To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChoroidal Melanoma
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedMay 2008
Primary CompletionJul 2012
TodayJul 2026
First PostedMay 20, 2008
Enrollment StartSep 1, 2007
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 18.1 years ago
Interventions
Ranibizumab injection and TTT - ICG baseddrug
Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.